NCT04539639 (AD) is a Phase 2 clinical trial of Jaktinib in Atopic Dermatitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Who is sponsoring NCT04539639?

NCT04539639 is sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

What drugs are being tested in NCT04539639?

Interventions in NCT04539639: Jaktinib, Jaktinib, Jaktinib, placebo.

What condition does NCT04539639 study?

NCT04539639 studies Atopic Dermatitis.

Is NCT04539639 still recruiting?

NCT04539639 is currently completed. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT04539639: AD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

Completed Phase 2 Last updated 24 March 2023

What this trial tests

Phase 2 trial testing Jaktinib in Atopic Dermatitis in 166 participants. Completed in 19 May 2022.

Timeline

2 December 2020

Primary endpoint
19 May 2022

19 May 2022

Quick facts

Lead sponsor	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	166
Start date	2 December 2020
Primary completion	19 May 2022
Estimated completion	19 May 2022
Sites	1 location across China

Drugs / interventions tested

Jaktinib — full drug profile →
Jaktinib — full drug profile →
Jaktinib — full drug profile →
placebo

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Jaktinib in participants with moderate to severe atopic dermatitis.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Bieber T. · · 2022 · cited 421× · PMID 34417579 · DOI 10.1038/s41573-021-00266-6
Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I, Pikiewicz W, Kaminiów K. · · 2023 · cited 6× · PMID 38138551 · DOI 10.3390/molecules28248064
Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.
Biliński K, Rakoczy K, Karwowska A, Cichy O, et al · · 2025 · cited 5× · PMID 40725743 · DOI 10.3390/jcm14145053
Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.
Nitulescu G, Olaru OT, Andrei C, Nitulescu GM, et al · · 2025 · cited 2× · PMID 40864813 · DOI 10.3390/cimb47080659
Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.
Tang A, Rachko G, Manzo Margiotta F, Levine J, et al · · 2026 · PMID 41969750 · DOI 10.2147/jir.s549496

Verify or expand the search:

Other trials of Jaktinib

Trials testing the same drug.

NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
NCT05255237 — Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata · Phase 3 · completed
NCT04866056 — Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. · Phase 1, PHASE2 · terminated
NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata · Phase 3 · completed
NCT04612699 — A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis · Phase 2 · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials

Trials by the same sponsor.

NCT05279001 — A Safety and Tolerability Study of Jaktinib · Phase 1 · unknown
NCT06193148 — A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants · Phase 1 · completed
NCT06132243 — Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions · Phase 1 · completed
NCT05864573 — Study of ZGGS15 in Patients With Advanced Solid Tumors · Phase 1 · completed
NCT05584800 — Study of ZGGS18 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04539639 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04539639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing